A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

296

Participants

Timeline

Start Date

December 2, 2016

Primary Completion Date

December 27, 2017

Study Completion Date

December 27, 2017

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

SAR425899

Self-administered by SC injection using a solution for injection in cartridge.

DRUG

Placebo

Self-administered by SC injection using a solution for injection in cartridge.

DRUG

Liraglutide

Self-administered by SC injection using a pre-filled pen.

DRUG

Metformin

Orally administered at a stable dose , \>=1500 mg daily stable dose or maximal tolerated dose.

Trial Locations (59)

1027

Investigational Site Number 3480002, Budapest

1042

Investigational Site Number 3480008, Budapest

1062

Investigational Site Number 3480005, Budapest

Investigational Site Number 3480006, Budapest

1213

Investigational Site Number 3480007, Budapest

8230

Investigational Site Number 3480001, Balatonfüred

10001

Investigational Site Number 8400022, New York

10115

Investigational Site Number 2760003, Berlin

15006

Investigational Site Number 7240001, A Coruña

15405

Investigational Site Number 7240007, Ferrol

19014

Investigational Site Number 2030002, Praha 9 - Klanovice

20852

Investigational Site Number 8400019, Rockville

28040

Investigational Site Number 7240002, Madrid

29010

Investigational Site Number 7240003, Málaga

Investigational Site Number 7240004, Málaga

33166

Investigational Site Number 8400025, Miami

34684

Investigational Site Number 8400007, Palm Harbor

35016

Investigational Site Number 7240006, Las Palmas de Gran Canaria

35660

Investigational Site Number 8400028, Sheffield

41071

Investigational Site Number 7240008, Seville

42500

Investigational Site Number 4840004, Actopan

44600

Investigational Site Number 4840001, Guadalajara

44670

Investigational Site Number 4840003, Guadalajara

48085

Investigational Site Number 8400003, Troy

58103

Investigational Site Number 8400005, Fargo

60827

Investigational Site Number 8400013, Chicago

64460

Investigational Site Number 4840002, Monterrey

67205

Investigational Site Number 8400016, Wichita

67207

Investigational Site Number 8400023, Wichita

70119

Investigational Site Number 8400018, New Orleans

75230

Investigational Site Number 8400006, Dallas

76800

Investigational Site Number 4840006, San Juan del Río

77079

Investigational Site Number 8400021, Houston

77478

Investigational Site Number 8400017, Sugar Land

78229

Investigational Site Number 8400026, San Antonio

78731

Investigational Site Number 8400004, Austin

79401

Investigational Site Number 2030001, Krnov

80209

Investigational Site Number 8400027, Denver

90017

Investigational Site Number 8400024, Los Angeles

90057

Investigational Site Number 8400001, Los Angeles

90255

Investigational Site Number 8400002, Huntington Park

93041

Investigational Site Number 8400012, Port Hueneme

190068

Investigational Site Number 6430002, Saint Petersburg

194358

Investigational Site Number 6430004, Saint Petersburg

195257

Investigational Site Number 6430001, Saint Petersburg

394018

Investigational Site Number 6430005, Voronezh

410030

Investigational Site Number 6430003, Saratov

48532-3447

Investigational Site Number 8400014, Flint

07036

Investigational Site Number 8400020, Linden

G1S 2L6

Investigational Site Number 1240008, Québec

G1W4R4

Investigational Site Number 1240005, Sainte-Foy

J1L 0H8

Investigational Site Number 1240002, Sherbrooke

M4G 3E8

Investigational Site Number 1240001, Toronto

V5Y 3W2

Investigational Site Number 1240003, Vancouver

370 01

Investigational Site Number 2030003, České Budějovice

104 00

Investigational Site Number 2030004, Praha 10 - Uhrineves

01307

Investigational Site Number 2760001, Dresden

06679

Investigational Site Number 2760006, Hohenmölsen

08035

Investigational Site Number 7240005, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY